RxDoctor Payments Data

Nicholas Mosca, MD

Family Medicine · Midwest City, OKNPI 1225568777

Payments from drug & device makers

$7,291in general payments, 2019–2025

Across 448 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$876
  • AstraZeneca$740
  • Lilly USA, LLC$740
  • Amgen$341
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$7,21899%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,291 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$129,704
Medicare patients
173
Services billed
3,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$59,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$33,900
JardianceEmpagliflozin20$19,845
FarxigaDapagliflozin Propanediol16$18,407
MounjaroTirzepatide17$17,630
RybelsusSemaglutide11$16,542
JanuviaSitagliptin Phosphate19$13,215
Xtampza ErOxycodone Myristate13$8,228
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,121
Albuterol Sulfate HfaAlbuterol Sulfate90$3,398
Gabapentin101$1,917
Varenicline Tartrate11$1,719
Citalopram HbrCitalopram Hydrobromide15$1,595
Levothyroxine Sodium132$1,504
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$876$76,23665 claims
GSKTrelegy Ellipta$1,109$33,90030 claims
AstraZenecaFarxiga, Breztri Aerosphere$740$26,52829 claims
Boehringer IngelheimJardiance$208$19,84520 claims
Lilly USA, LLCMounjaro$740$17,63017 claims
MerckJanuvia$210$13,21519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →